Novartis

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.

Key Points: 
  • BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones.
  • In the monotherapy dose escalation arm, patients have cleared all planned dosing cohorts of 0.3, 1, 3, 10 and 15 mg/kg.
  • Anticipated milestones for the SNS-101 Phase 1/2 clinical trial include:
    Sensei announces that Ron Weitzman, M.D., F.A.C.P., has joined Sensei as part-time Chief Medical Officer.
  • As a result, Sensei will pause IND-enabling work on its preclinical-stage TMAb programs, including SNS-102 (VSIG4), SNS-103 (CD39) and SNS-201 (VISTAxCD28).

Former Biogen CEO Michel Vounatsos Joins Quris-AI Board

Retrieved on: 
Thursday, January 4, 2024

BOSTON and TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Quris-AI , an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, announced the addition of Michel Vounatsos, former CEO of Biogen, to its Board of Directors, and the appointment of Yossi Ben Amram, former Merck & Co., Inc. (MSD) Regional President, as President of Quris-AI.

Key Points: 
  • BOSTON and TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Quris-AI , an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, announced the addition of Michel Vounatsos, former CEO of Biogen, to its Board of Directors, and the appointment of Yossi Ben Amram, former Merck & Co., Inc. (MSD) Regional President, as President of Quris-AI.
  • “Adding accomplished pharmaceutical leaders such as Yossi Ben Amram and Michel Vounatsos to our leadership team will be invaluable in our push for a pharma Bio-AI revolution.
  • Michel Vounatsos brings extensive global leadership and management experience in the biopharmaceutical industry, including having served as CEO and member of the Board of Directors of Biogen, Inc. from early 2017 until November 2022.
  • Vounatsos earned his MBA from the HEC School of Management in Paris, France, and his C.S.C.T.

EF Hutton Appoints David Sans as Head of Healthcare

Retrieved on: 
Wednesday, January 3, 2024

NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.

Key Points: 
  • NEW YORK, NY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- EF Hutton, an investment bank headquartered in New York, today announced the appointment of David Sans, PhD, FAARM MBA, as Managing Director, Head of Healthcare, to lead the Company’s Healthcare & Life Sciences Investment Banking Team.
  • David Sans, PhD, FAARM MBA, brings many years of biotech and pharma experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.
  • “We continue to see innovation and opportunity across the healthcare continuum in biotechnology, medical devices, healthcare IT, healthcare services, and therapeutics, and are privileged to have someone of David’s caliber serve as Head of Healthcare,” said Joseph T. Rallo, Chief Executive Officer of EF Hutton.
  • He will oversee all healthcare transactions at EF Hutton, spearheading and driving a wide range of industry transactions.

NSF Welcomes Dean Bergy and Nancy Lurker to Board of Directors

Retrieved on: 
Wednesday, January 3, 2024

NSF , the leading global public health and safety organization, today announced the appointment of Dean Bergy and Nancy Lurker to its Board of Directors.

Key Points: 
  • NSF , the leading global public health and safety organization, today announced the appointment of Dean Bergy and Nancy Lurker to its Board of Directors.
  • “Dean Bergy and Nancy Lurker are welcome additions to our NSF Board of Directors,” said Pedro Sancha, President and CEO, NSF.
  • He also served on the board of directors of RTI Biologics, Inc. from 2010 to 2016, including as the Board Chair and Audit Committee Chair.
  • In joining the NSF Board of Directors, I look forward to supporting this impactful work.”
    Lurker is recognized for her diverse experience in the pharmaceutical and biotechnology industries.

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

Retrieved on: 
Wednesday, January 3, 2024

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102 ( NCT05680922 ).1 Under the terms of the license agreement closed today, Legend Biotech will receive a $100 million upfront cash payment.

Key Points: 
  • Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, closed its previously announced exclusive, worldwide license agreement with Novartis Pharma AG (Novartis) for certain Legend Biotech chimeric antigen receptor T-cell (CAR-T) cell therapies targeting Delta-like ligand protein 3 (DLL3), including Legend Biotech’s existing autologous CAR-T cell therapy candidate, LB2102 ( NCT05680922 ).1 Under the terms of the license agreement closed today, Legend Biotech will receive a $100 million upfront cash payment.

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.

Key Points: 
  • WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.
  • “Jean-Marie has over twenty years of successful experience in oncology drug development, and we are delighted to have him join Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • “During his impressive career, he has effectively executed on advancing drugs from early development through regulatory approval, at both pharma and biotech companies.
  • Prior to Dragonfly, Dr. Cuillerot was the chief medical officer of Agenus, where he led development activities for five investigational therapies.

Switch Therapeutics Appoints Charles Allerson, Ph.D., as Chief Technology Officer

Retrieved on: 
Wednesday, January 3, 2024

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat diseases utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the appointment of Charles Allerson, Ph.D., as Chief Technology Officer (CTO).
  • He succeeds Si-ping Han, Ph.D., co-founder of Switch Therapeutics, who will transition to an advisory role and serve on Switch’s Scientific Advisory Board.
  • “Charles joins our leadership team with extensive expertise in oligonucleotide chemistry and RNA-based therapeutics, and we are delighted to welcome him to Switch.
  • He will play a crucial role as we continue driving our novel CASi platform forward for the treatment of central nervous system (CNS) diseases,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.

ProMIS Neurosciences, Inc. Announces Leadership Transition

Retrieved on: 
Wednesday, January 3, 2024

Mr. Warma’s appointment is expected to provide a seamless transition as the Company remains focused on advancing the ongoing clinical program for PMN310 in Alzheimer’s disease and forging strategic partnerships to accelerate ProMIS’ broad potential for groundbreaking drug development.

Key Points: 
  • Mr. Warma’s appointment is expected to provide a seamless transition as the Company remains focused on advancing the ongoing clinical program for PMN310 in Alzheimer’s disease and forging strategic partnerships to accelerate ProMIS’ broad potential for groundbreaking drug development.
  • His leadership and his neuroscience background, combined with a profound understanding of our mission in novel drug development, positions the Company well for growth during this transition period," said Gene Williams, Chairman of the Board of ProMIS.
  • “We thank Dr. Farfel for her contributions and leadership during her tenure at ProMIS and wish her continued success in her endeavors,” added Mr. Williams.
  • Mr. Warma has held senior leadership positions at several biotech and pharma companies, including Novartis, Opexa Therapeutics and I-Mab BioPharma, Inc.

Narcolepsy Drugs Market, Size, Global Forecast 2024-2030: Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023

The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Narcolepsy Drugs Market is poised for substantial growth, with a projected value of US$5.95 billion by 2030
    Several factors contribute to the expansion of the narcolepsy drugs market.
  • The Narcolepsy Drugs Market is expected to grow steadily, with a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030.
  • Combined, these elements make the U.S. narcolepsy drugs market a leader in global healthcare.

EQS-News: Dr. Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma

Retrieved on: 
Saturday, December 30, 2023

Laupheim, Germany, December 4, 2023 – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Dr. Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective December 1, 2023.

Key Points: 
  • Laupheim, Germany, December 4, 2023 – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Dr. Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective December 1, 2023.
  • In this role, he is heading the Site Leadership Team in Laupheim and is part of the Global Leadership Team.
  • Christiane Bardroff, COO of Rentschler Biopharma, said: “The appointment of Günter Stempfer as Site Head for Laupheim is an optimal solution.
  • Dr. Stempfer joined Rentschler Biopharma on January 1, 2022, as Head of Global Strategic Development.